Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
Enliven Therapeutics (ELVN) reached FDA agreement on the Phase 3 trial design for relcobatinib (ELVN-001) in treating chronic myeloid leukemia. The ENABLE-2 trial will compare relcobatinib to second-generation TKIs, with a target enrollment of 450 patients. The company plans to initiate the trial by year-end 2026.
How this was made
The 30-second read
Why it matters
Regulatory alignment is a critical de‑risking milestone that often triggers short‑term price appreciation for biotech firms.
Market read
The announcement provides fresh, material information that could influence trading decisions on ELVN.
What to watch
Potential competition from other BCR::ABL1 inhibitors and the need for successful enrollment could delay benefits.
Background
Enliven Therapeutics is a clinical-stage biotech focused on small‑molecule therapies for cancer. The ENABLE-2 trial will compare its candidate relcobatinib against second‑generation TKIs in previously treated CML patients.
Ticker impact
Enliven Therapeutics announced FDA alignment on the design of the ENABLE-2 Phase 3 trial for relcobatinib.
likely upward pressure as investors price in reduced regulatory risk and potential market opportunity.
First disclosure of trial design alignment; biotech stocks typically rally on such milestones.
Market effects
May boost sentiment for the broader CML and oncology biotech sector as a peer clears a regulatory step.
Limited to U.S. biotech investors; no broader regional effect.
Modest, confined to specialty pharma investors worldwide.
Counterpoint
If the trial fails to meet endpoints, the early alignment could be overstated, leading to a sell-off.
Key entities
- companyEnliven Therapeutics
Clinical‑stage biopharma developing relcobatinib for chronic myeloid leukemia.
- regulatorFDA
U.S. Food and Drug Administration that approved the trial design.
